TNGX Tango Therapeutics, Inc.
Pharmaceutical Preparations · Nasdaq · SEC CIK 1819133 · Fiscal year ends 12/31
Financial factors as of 2026-06-30 (2026Q2), TTM = sum of the last four quarters
Growth
TTM revenue YoY121.5%
TTM net income YoY15.0%
TTM EPS YoY36.4%
Revenue 3-yr CAGR16.9%
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin-253.4%
Net margin-229.9%
FCF margin-268.1%
EBITDA margin-249.8%
Returns
ROE-21.3%
ROA-18.9%
ROIC (approx.)-28.5%
Asset turnover0.08x
Leverage & solvency
Liabilities / assets4.6%
Debt / equity0.00x
Current ratio50.82x
Interest coverage—
Cash quality & payout
Operating cash flow / net income1.16x
Accruals ratio3.1%
Payout ratio—
Capex / revenue0.7%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 |
|---|---|---|
| Income statement | ||
| Revenue | $62.38M | $42.07M |
| R&D expense | $132.16M | $143.92M |
| SG&A expense | $41.51M | $43.75M |
| Operating income | -$111.29M | -$145.59M |
| Pretax income | -$101.59M | -$130.09M |
| Income tax | $4,000 | $208,000 |
| Net income | -$101.59M | -$130.30M |
| EBITDA | -$109.01M | -$143.10M |
| EPS (basic) | -0.87 | -1.19 |
| EPS (diluted) | -0.87 | -1.19 |
| Weighted avg. shares (diluted) | 116.17M | 109.23M |
| Banking | ||
| Net interest income | $5.63M | $7.89M |
| Balance sheet | ||
| Cash & equivalents | $112.28M | $69.53M |
| Short-term investments | $230.86M | $188.39M |
| Current assets | $353.76M | $266.34M |
| PP&E, net | $6.87M | $8.10M |
| Total assets | $398.69M | $316.49M |
| Current liabilities | $21.68M | $38.17M |
| Total liabilities | $52.51M | $116.97M |
| Shareholders' equity | $346.18M | $199.52M |
| Shares outstanding | 135.94M | 107.73M |
| Cash flow statement | ||
| Operating cash flow | -$138.89M | -$131.50M |
| Capital expenditure | $1.05M | $754,000 |
| Free cash flow | -$139.93M | -$132.25M |
| Investing cash flow | -$40.87M | $86.13M |
| Financing cash flow | $222.50M | $47.66M |
| Depreciation & amortization | $2.28M | $2.50M |
| Stock-based compensation | $26.43M | $28.90M |
Free plan shows the latest 2 periods; Pro shows all 6 🔒
· This company does not report gross profit in XBRL.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.